4-<(diethylphosphono)methyl>pyridine-2-carboxamide | 113190-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-<(diethylphosphono)methyl>pyridine-2-carboxamide
• 英文别名: 4-(Diethylphosphonomethyl)-2-pyridinecarboxamide；4-(diethoxyphosphorylmethyl)pyridine-2-carboxamide
• CAS: 113190-80-0
• 化学式: C₁₁H₁₇N₂O₄P
• 分子量: 272.241
• InChiKey: DBGQJKPCYUSWPL-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C
• 沸点：
  452.4±40.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  91.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-<(diethylphosphono)methyl>pyridine-2-carboxamide 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 溶剂黄146 为溶剂， 25.0 ℃ 、275.79 kPa 条件下， 反应 22.0h， 生成 selfotel
  参考文献：
  名称：

  4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors and anticonvulsant activity

  摘要：

  A series of 4-(phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids were synthesized, and their biological activity was assessed as competitive ligands for the NMDA receptor, both in vitro by using a receptor binding assay ([3H]CGS 19755 binding) and in vivo by using an NMDA seizure model in mice. The analogues were also evaluated in [3H]AMPA and [3H]kainate binding to assess their affinity for non-NMDA excitatory amino acid receptor subtypes. A number of these analogues show potent and selective NMDA antagonistic activity both in vitro and in vivo. Most notable are 4-(phosphonomethyl)-2-piperidinecarboxylic acid (1a) (CGS 19755) and the phosphonopropenyl analogue 1i, both of which show anticonvulsant activity in the 1-2 mg/kg ip range. With the aid of computer-assisted modeling, a putative bioactive conformation for AP-5 is hypothesized from the SAR data presented and a preliminary model for the antagonist-preferring state of the NMDA receptor is presented.

  DOI：

  10.1021/jm00129a025
• 作为产物：
  描述：

  2-氰基-4-[(二乙基膦酰基)甲基]吡啶 在 硫酸 作用下， 反应 0.17h， 以71%的产率得到4-<(diethylphosphono)methyl>pyridine-2-carboxamide
  参考文献：
  名称：

  4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors and anticonvulsant activity

  摘要：

  A series of 4-(phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids were synthesized, and their biological activity was assessed as competitive ligands for the NMDA receptor, both in vitro by using a receptor binding assay ([3H]CGS 19755 binding) and in vivo by using an NMDA seizure model in mice. The analogues were also evaluated in [3H]AMPA and [3H]kainate binding to assess their affinity for non-NMDA excitatory amino acid receptor subtypes. A number of these analogues show potent and selective NMDA antagonistic activity both in vitro and in vivo. Most notable are 4-(phosphonomethyl)-2-piperidinecarboxylic acid (1a) (CGS 19755) and the phosphonopropenyl analogue 1i, both of which show anticonvulsant activity in the 1-2 mg/kg ip range. With the aid of computer-assisted modeling, a putative bioactive conformation for AP-5 is hypothesized from the SAR data presented and a preliminary model for the antagonist-preferring state of the NMDA receptor is presented.

  DOI：

  10.1021/jm00129a025

文献信息

• Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof
  申请人：Ciba-Geigy Corporation

  公开号：US04906621A1

  公开（公告）日：1990-03-06

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxy-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及公式I的膦酸：##STR1## 其中，膦酸基团的一个或两个酸性羟基可以以药学上可接受的单酯或双酯的形式进行官能化；其中，Y代表选择性取代的2-羧基吡咯烷基、2-羧基-2,5-二氢吡咯基、2-羧基-1,2,3,6-四氢吡啶基、2-羧基-1,2,5,6-四氢吡啶基、2-羧基哌啶基、2-羧基四氢喹啉基或2-羧基过氢喹啉基，2-羧基-2,3-二氢吲哚基或2-羧基过氢吲哚基，其中每个羧基可以以药学上可接受的酯或酰胺的形式进行官能化；A代表直接键，低烯基，低基亚烷基或低基亚基烷基，但当Y代表2-羧基吡咯烷基时，A不代表直接键；以及其药学上可接受的盐；它们对哺乳动物的神经系统疾病的治疗和作为N-甲基-D-天门冬氨酸敏感性兴奋性氨基酸受体的拮抗剂是有用的。
• Certain phosphonic acid quinoline-2-carboxylic acids, esters or amides
  申请人：Ciba-Geigy Corporation

  公开号：US05217963A1

  公开（公告）日：1993-06-08

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸：##STR1## 其中膦酸基团的一个或两个酸性羟基可以以药学上可接受的单酯或双酯的形式进行官能化；其中Y代表可以选择取代的2-羧基四氢喹啉基或2-羧基戊二氢喹啉基，其中羧基可以以药学上可接受的酯或酰胺的形式进行官能化；A代表直接键，低烯基，低烷基亚甲基或低烷基；以及其药学上可接受的盐；它们对哺乳动物的神经系统疾病治疗和作为N-甲基-D-天门冬氨酸敏感性兴奋性氨基酸受体的拮抗剂是有用的。
• Certain phosphonic acids and derivatives useful for the treatment of
  申请人：Ciba-Geigy Corporation

  公开号：US05057506A1

  公开（公告）日：1991-10-15

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represent optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxyetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxyl-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutical acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸，其中膦酸基团中的一个或两个酸性羟基可以以药学上可接受的单酯或二酯的形式进行官能化；其中Y代表可选择取代的2-羧基吡咯烷基，2-羧基-2,5-二氢吡咯基，2-羧基-1,2,3,6-四氢吡啶基，2-羧基-1,2,5,6-四氢吡啶基，2-羧基哌啶基，2-羧基四氢喹啉基或2-羧基过氢喹啉基，2-羧基-2,3-二氢吲哚基或2-羧基过氢吲哚基，如本文所述，在其中羧基可以以药学可接受的酯或酰胺的形式进行官能化；A代表直接键，较低的烯基，较低的烷基亚甲基或较低的烷基，但当Y代表2-羧基吡咯烷基时，A不代表直接键；以及其药学可接受的盐；它们对哺乳动物的神经系统疾病的治疗和作为N-甲基-D-天门冬氨酸敏感性兴奋性氨基酸受体的拮抗剂是有用的。
• Certain 2-carboxypiperidyl-(alkylene or alkenylene)-phosphonic acids and
  申请人：Ciba-Geigy Corporation

  公开号：US04898854A1

  公开（公告）日：1990-02-06

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxy-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸： 其中，膦酸基团的一个或两个酸性羟基可以作为药学上可接受的单酯或双酯的形式进行官能化；其中，Y代表可选取代的2-羧基吡咯烷基、2-羧基-2,5-二氢吡咯基、2-羧基-1,2,3,6-四氢吡啶基、2-羧基-1,2,5,6-四氢吡啶基、2-羧基哌啶基、2-羧基四氢喹啉基或2-羧基过氢喹啉基、2-羧基-2,3-二氢吲哚基或2-羧基过氢吲哚基，其中每个羧基可以作为药学上可接受的酯或酰胺的形式进行官能化；A代表直接键、较低的烯烃基、较低的烷基亚烷基或较低的烷基，但当Y代表2-羧基吡咯烷基时，A不代表直接键；以及其药学上可接受的盐。本发明的膦酸在哺乳动物的神经系统疾病治疗中有用，并作为N-甲基-D-天门冬氨酸敏感的兴奋性氨基酸受体的拮抗剂。
• Certain phosphonic acids and derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0203891B1

  公开（公告）日：1991-05-15